Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tariquidar

Generic Name: Tariquidar

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₃₈N_₄O_₆

CAS Number: 206873-63-4

Unique Ingredient Identifier: J58862DTVD

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in ovarian cancer, lung cancer, and breast cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy

Phase 2

Completed

Posted: 2004/05/06

Sponsor:National Cancer Inst...

ID:NCT00082368

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

Phase 2

Completed

Posted: 2003/09/16

Sponsor:National Cancer Inst...

ID:NCT00069160

Vinorelbine and XR9576 to Treat Cancer

Phase 1

Completed

Posted: 2002/12/10

Sponsor:National Cancer Inst...

ID:NCT00001944

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Terminated

Posted: 2002/08/01

Sponsor:QLT Inc.

ID:NCT00042302

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Terminated

Posted: 2002/08/01

Sponsor:QLT Inc.

ID:NCT00042315

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy